Abuse and diversion of buprenorphine sublingual tablets and film

Journal of Substance Abuse Treatment

Volumn 47, Issue 1, 2014, Pages 27-34

  Lavonas, Eric J ^a   Severtson, S Geoffrey ^a   Martinez, Erin M ^a   Bucher Bartelson, Becki ^a   Le Lait, Marie Claire ^a   Green, Jody L ^a   Murrelle, Lenn E ^b   Cicero, Theodore J ^c   Kurtz, Steven P ^d   Rosenblum, Andrew ^e   Surratt, Hilary L ^d   Dart, Richard C ^a  

^a ROCKY MOUNTAIN POISON AND DRUG CENTER   (United States)

^b Venebio Group LLC   (United States)

^c WASHINGTON UNIVERSITY   (United States)

^d NOVA SOUTHEASTERN UNIVERSITY   (United States)

^e NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES   (United States)

Author keywords

Buprenorphine; Drug abuse; Drug formulations; Substance related disorders

Indexed keywords

BUPRENORPHINE; NALOXONE; NARCOTIC AGENT; TABLET;

ADDICTION; ARTICLE; DRUG ABUSE; DRUG BIOAVAILABILITY; DRUG FORMULATION; HEALTH SURVEY; HUMAN; POISON CENTER; PRESCRIPTION; PRESCRIPTION DRUG DIVERSION; PRIORITY JOURNAL; TABLET; TABLET FORMULATION; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; QUESTIONNAIRE; STATISTICS AND NUMERICAL DATA; SUBLINGUAL DRUG ADMINISTRATION; UNITED STATES; UNIVERSITY;

ADMINISTRATION, SUBLINGUAL; BUPRENORPHINE; HUMANS; NARCOTICS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; POISON CONTROL CENTERS; PRESCRIPTION DRUG DIVERSION; QUESTIONNAIRES; TABLETS; UNITED STATES; UNIVERSITIES;

EID: 84899965465     PISSN: 07405472     EISSN: 18736483     Source Type: Journal    
DOI: 10.1016/j.jsat.2014.02.003     Document Type: Article

References (32)

1. AAPCC National Poison Data System (NPDS(R) Reference Manual. Part 2 - System information manual 2007, American Association of Poison Control Centers, Washington, D.C.
2. Amass L., Ling W., Freese T.E., Reiber C., Annon J.J., Cohen A.J., et al. Bringing buprenorphine-naloxone detoxification to community treatment providers: The NIDA Clinical Trials Network field experience. American Journal on Addictions 2004, 13(Suppl 1):S42-S66.
3. Auriacombe M., Fatseas M., Dubernet J., Daulouede J.P., Tignol J. French field experience with buprenorphine. American Journal on Addictions 2004, 13(Suppl 1):S17-S28.
4. Cicero T.J., Ellis M.S., Surratt H.L. Effect of abuse-deterrent formulation of OxyContin. New England Journal of Medicine 2012, 367:187-189.
5. Cicero T.J., Surratt H.L., Inciardi J. Use and misuse of buprenorphine in the management of opioid addiction. Journal of Opioid Management 2007, 3:302-308.
6. Comer S.D., Collins E.D. Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers. Journal of Pharmacology and Experimental Therapeutics 2002, 303:695-703.
7. Daniulaityte R., Falck R., Carlson R.G. Illicit use of buprenorphine in a community sample of young adult non-medical users of pharmaceutical opioids. Drug and Alcohol Dependence 2012, 122:201-207.
8. Dart R.C., Cicero T.J., Surratt H.L., Rosenblum A., Bartelson B.B., Adams E.H. Assessment of the abuse of tapentadol immediate release: The first 24months. Journal of Opioid Management 2012, 8:395-402.
9. Dasgupta N., Bailey E.J., Cicero T., Inciardi J., Parrino M., Rosenblum A., et al. Post-marketing surveillance of methadone and buprenorphine in the United States. Pain Medicine 2010, 11:1078-1091.
10. FDA Subutex and suboxone approved to treat opioid dependence Retrieved December 11, 2012 from. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm191521.htm.
11. Fiellin D.A., O'Connor P.G. Clinical practice. Office-based treatment of opioid-dependent patients. New England Journal of Medicine 2002, 347:817-823.
12. Fudala P.J., Johnson R.E. Development of opioid formulations with limited diversion and abuse potential. Drug and Alcohol Dependence 2006, 83(Suppl 1):S40-S47.
13. Hakansson A., Medvedeo A., Andersson M., Berglund M. Buprenorphine misuse among heroin and amphetamine users in Malmo, Sweden: Purpose of misuse and route of administration. European Addiction Research 2007, 13:207-215.
14. Inciardi J.A., Surratt H.L., Cicero T.J., Kurtz S.P., Martin S.S., Parrino M.W. The "black box" of prescription drug diversion. Journal of Addictive Diseases 2009, 28:332-347.
15. Johanson C.E., Arfken C.L., di Menza S., Schuster C.R. Diversion and abuse of buprenorphine: Findings from national surveys of treatment patients and physicians. Drug and Alcohol Dependence 2012, 120:190-195.
16. Johnson R.E., Jaffe J.H., Fudala P.J. A controlled trial of buprenorphine treatment for opioid dependence. JAMA 1992, 267:2750-2755.
17. Maremmani I., Pani P.P., Pacini M., Perugi G. Substance use and quality of life over 12months among buprenorphine maintenance-treated and methadone maintenance-treated heroin-addicted patients. Journal of Substance Abuse Treatment 2007, 33:91-98.
18. Mattick R.P., Kimber J., Breen C., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews 2008, CD002207.
19. Mendelson J., Jones R.T. Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: Why the 4:1 ratio for treatment?. Drug and Alcohol Dependence 2003, 70(2 Suppl):S29-S37.
20. Monte A.A., Mandell T., Wilford B.B., Tennyson J., Boyer E.W. Diversion of buprenorphine/naloxone coformulated tablets in a region with high prescribing prevalence. Journal of Addictive Diseases 2009, 28:226-231.
21. Schuman-Olivier Z., Albanese M., Nelson S.E., Roland L., Puopolo F., Klinker L., et al. Self-treatment: Illicit buprenorphine use by opioid-dependent treatment seekers. Journal of Substance Abuse Treatment 2010, 39:41-50.
22. Schwarz R., Zelenev A., Bruce R.D., Altice F.L. Retention on buprenorphine treatment reduces emergency department utilization, but not hospitalization, among treatment-seeking patients with opioid dependence. Journal of Substance Abuse Treatment 2012, 43:451-457.
23. Severtson S.G., Bartelson B.B., Davis J.M., Munoz A., Schneider M.F., Chilcoat H., et al. Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010. [Research Support, Non-U.S. Gov't]. The journal of pain : official journal of the American Pain Society 2013, 14:1122-1130.
24. Smith M.Y., Schneider M.F., Wentz A., Hughes A., Haddox J.D., Dart R. Quantifying morbidity associated with the abuse and misuse of opioid analgesics: A comparison of two approaches. Clinical Toxicology (Philadelphia, Pa.) 2007, 45:23-30.
25. Strang J. Abuse of buprenorphine. Lancet 1985, 2:725.
26. Sullivan L.E., Moore B.A., Chawarski M.C., Pantalon M.V., Barry D., O'Connor P.G., et al. Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. Journal of Substance Abuse Treatment 2008, 35:87-92.
27. Uosukainen H., Kauhanen J., Voutilainen S., Fohr J., Paasolainen M., Tiihonen J., et al. Twelve-year trend in treatment seeking for buprenorphine abuse in Finland. Drug and Alcohol Dependence 2013, 127:207-214.
28. Walsh S.L., Eissenberg T. The clinical pharmacology of buprenorphine: Extrapolating from the laboratory to the clinic. Drug and Alcohol Dependence 2003, 70(2 Suppl):S13-S27.
29. Walsh S.L., Preston K.L., Stitzer M.L., Cone E.J., Bigelow G.E. Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clinical Pharmacology and Therapeutics 1994, 55:569-580.
30. Winter E.J., Davis J., Bucher-Bartelson B., Westberry R., Green J.L., Lavonas E.J. Systematic misclassification in product-specific coding of poison center data: The example of buprenorphine in the RADARS® System Poison Center program. Clinical Toxicology (Philadelphia, Pa.) 2012, 50.
31. Winter E.J., Martinez E.M., Lavonas E.J., Bucher Bartelson B., Poppish L., Green J.L., et al. Micromedex® Clarification of Suboxone® Products Increases Coding Accuracy in the RADARS® System Poison Center Program. Paper presented at the North American Congress of Clinical Toxicology (NACCT) Annual Meeting, Atlanta, GA 2013, September.
32. Yokell M.A., Zaller N.D., Green T.C., Rich J.D. Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: An international review. Current Drug Abuse Reviews 2011, 4:28-41.